MC2 Therapeutics A/S announces first patient dosed in EU Phase 3 trial in psoriasis vulgaris
POSTED: January 6, 2019
- First patient dosed in Phase 3 trial assessing the safety and efficacy of MC2-01 Cream in EU
- Topline results are expected in Q3 2019
Copenhagen, January 6th, 2019 – MC2 Therapeutics A/S, ...
READ FULL ARTICLE >
